VTT Technical Research Center of Finland is the leading research and technology company in the Nordic countries. It provides expert services for Finnish and international partners in both private and public sector. Research groups in VTT and at the University of Eastern Finland (UEF) are behind the original discoveries that are the basis of Desentum’s allergen immunotherapeutic products. The research-scale production and purification of all the new product candidates is performed in VTT.
Research groups in VTT and at the University of Eastern Finland (UEF) are behind the original discoveries that are the basis of Desentum’s allergen immunotherapeutic products. The Department of Chemistry at UEF has world-class expertise in advanced mass spectrometry. The department is a home to a state-of-the-art high-resolution FT-ICR mass spectrometer that is one of the few of its kind in Europe. This technology is very valuable in determining the correct folding and structure of Desentum’s product candidates as well as providing information on allergen-IgE complexes.
RefLab is a Danish company specializing in allergy diagnostics. They have developed a histamine release test (HR-test® system) that can be used to diagnose patients with various allergies. They also collaborate with universities, university hospitals and pharmaceutical industry in R&D related to allergies. RefLab performs histamine release assays (HRA) on Desentum’s product candidates. The assays are the first line in evaluating the candidate molecules’ potential as immunotherapeutic products.
IRAS is an interfacultary research institute within the faculties of Veterinary Medicine, Medicine and Sciences of Utrecht University. It provides education and research on the human health risks of exposure to potentially harmful agents in the environment, at the workplace and through the food chain. Effects on ecosystems are also considered. IRAS has tested Desentum’s product candidates in a mouse model for safety and immunogenicity.
Biovian is a one-stop-shop in GMP contract manufacturing of biopharmaceuticals covering services from early development to finished vial. Biovian's 2700 m2 facilities are EMA certified and FDA inspected for cGMP production of investigational and commercial products. The GMP manufacturing of Desentum’s recombinant hypoallergens is optimized and carried out at Biovian.